Identification of oleamide in <em>Guatteria</em> recurvisepala by LC/MS-Based <em>Plasmodium falciparum</em> thioredoxin reductase ligand binding... (Publications)
current research on applications of mass spectrometry to natural product drug discovery against malaria aims to screen plant extracts for new ligands to PLASMODIUM FALCIPARUM thioredoxin reductase ( PFTrxR) [...] regulation of the parasite and is validated as a promising target for therapeutic intervention against malaria. In the present study, detannified methanol extracts from GUATTERIA RECURVISEPALA, LICANIA KALLUNKIAE
Discovery and structure-activity relationships of pyrrolone antimalarials (Publications)
2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways
New 2‑aminopyrimidine derivatives and their antitrypanosomal and antiplasmodial activities (Publications)
of sleeping sickness, Trypanosoma brucei rhodesiense, as well as against a causative organism of malaria, Plasmodium falciparum NF54. Their cytotoxic properties were determined with L-6 cells (rat skeletal
Christian Selinger (People)
https://www.swisstph.ch/en/staff/profile/people/christian-selinger
in pathogens and diseases affecting humans such as HIV, Influenza, Polio, HPV, Coronaviruses and Malaria.
Aurélie Jeandron (People)
https://www.swisstph.ch/en/staff/profile/people/aurelie-jeandron
operational challenges posed by resource-limited settings. She recently broadened her expertise to malaria modelling, after having focused on water, sanitation and hygiene and environmental health. Education
Sophie Diarra (People)
https://www.swisstph.ch/en/staff/profile/people/sophie-diarra
of the Health Interventions Unit at Swiss TPH, Sophie is currently investigating key factors in malaria control, applying a socio-epidemiological approach in Papua New Guinea . Her key interests lie in
Aita Signorell (People)
https://www.swisstph.ch/en/staff/profile/people/aita-signorell
circumstances in resource limited settings and designed for poverty-related diseases like tuberculosis, malaria and sleeping sickness. Dr. Signorell’s primary interest lies in the field of community-centered medicines
New 2‑aminopyrimidine derivatives and their antitrypanosomal and antiplasmodial activities (Publications)
of sleeping sickness, Trypanosoma brucei rhodesiense, as well as against a causative organism of malaria, Plasmodium falciparum NF54. Their cytotoxic properties were determined with L-6 cells (rat skeletal
Discovery and structure-activity relationships of pyrrolone antimalarials (Publications)
2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways
Declining burden of <em>Plasmodium vivax</em> in a population in northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription... (Publications)
and artemisinin-based therapy, species-specific diagnostics, and bed net usage all of which reduce malaria transmission but not P. vivax relapse. In the absence of widespread primaquine use for radical cure